Hormones & metabolism Secretin hormone
Secretin
Regulatory status
Status at a glance
503A compounding status
Not nominated
We found no pending nomination for the 503A bulks list. Unless the substance has another legal pathway (for example, a USP monograph or use in an FDA-approved drug), 503A pharmacies generally may not compound with it.
- FDA approval
- An FDA-approved product contains this peptide
- 503B outsourcing
- Not determined
- Anti-doping (WADA)
- Not on the WADA Prohibited List
- DEA schedule
- Not a controlled substance
About peptide status
Most peptides discussed here are not FDA-approved for any use, and products labeled “research use only” are not for human use. Removal from Category 2 does not authorize compounding. PCAC votes are non-binding recommendations; FDA and HHS make the final decisions.
This is not medical or legal advice, and we do not publish dosing, sourcing or reconstitution information. Talk with a licensed clinician before using any peptide.
If you think you are having a medical emergency, call 911.
Key takeaway
Secretin (sold as ChiRhoStim) is a gastrointestinal hormone used as a diagnostic agent to stimulate the pancreas and measure how well it secretes. It was the very first substance ever called a "hormone," discovered in 1902, and today its synthetic form helps evaluate pancreatic function and detect gastrinoma. The human secretin product has been FDA-approved in the U.S. since 2004 and is given by injection during a diagnostic test.
At a glance
- What it is
- A 27-amino-acid gastrointestinal hormone used as a diagnostic stimulant
- Approved for
- Assessing pancreatic exocrine function, diagnosing gastrinoma, and aiding duct identification during ERCP
- Key fact
- Secretin-stimulated imaging detects pancreatic duct abnormalities more sensitively than imaging alone
- Route
- Intravenous injection
- Evidence strength
- FDA approved
Summary
Secretin is the first hormone ever discovered and an FDA-approved diagnostic agent. Learn how it tests pancreatic function and what the evidence shows.
What is secretin?
Secretin is a 27-amino-acid hormone normally released by the small intestine to signal the pancreas to secrete a bicarbonate-rich fluid that neutralizes stomach acid. The FDA-approved product, ChiRhoStim, is synthetic human secretin used not as a treatment but as a diagnostic agent that provokes a measurable pancreatic or gastric response. An earlier synthetic porcine secretin product has since been discontinued in favor of the human form.
The history of secretin
Secretin holds a unique place in medical history: it was the first hormone ever identified. In 1902, the physiologists William Bayliss and Ernest Starling showed that a substance released from the intestinal lining traveled through the blood to stimulate the pancreas, and Starling later coined the word "hormone" to describe such chemical messengers. Secretin therefore marks the beginning of endocrinology as a field, though its modern clinical role is diagnostic rather than therapeutic.
How does secretin work?
Secretin binds secretin receptors on the duct and acinar cells of the pancreas, stimulating secretion of a watery, bicarbonate-rich fluid. In a diagnostic test, giving secretin and then sampling or imaging the pancreatic output shows how well the gland can respond, which helps evaluate suspected exocrine pancreatic dysfunction. Secretin also stimulates gastrin release from the abnormal cells of a gastrinoma, producing a characteristic paradoxical rise in gastrin that helps confirm that tumor.
Because the test depends on the measured response, secretin is given as a single intravenous dose under controlled conditions. In clinical studies, secretin-enhanced imaging detected pancreatic duct abnormalities with higher sensitivity than imaging without stimulation.
Is it FDA-approved?
Editor’s note
Status: Yes. Synthetic human secretin (ChiRhoStim) was approved by the FDA in 2004 for these diagnostic uses: Diagnostic use | What secretin does Diagnosis of exocrine pancreatic dysfunction | Stimulates pancreatic secretions Diagnosis of gastrinoma | Stimulates gastrin secretion Endoscopic retrograde cholangiopancreatography (ERCP) | Helps identify the pancreatic ducts
Category: FDA-approved · Primary body area: Hormones & metabolism
Yes. Synthetic human secretin (ChiRhoStim) was approved by the FDA in 2004 for these diagnostic uses:
| Diagnostic use | What secretin does |
|---|---|
| Diagnosis of exocrine pancreatic dysfunction | Stimulates pancreatic secretions |
| Diagnosis of gastrinoma | Stimulates gastrin secretion |
| Endoscopic retrograde cholangiopancreatography (ERCP) | Helps identify the pancreatic ducts |
What is secretin prescribed for?
Secretin is used as a diagnostic aid in three settings: evaluating pancreatic exocrine function, provoking a gastrin response to help diagnose gastrinoma, and facilitating duct visualization during ERCP. It is administered by a clinician as part of a specific test, not taken on an ongoing basis.
What are the side effects?
According to the prescribing information, the most common side effects of a single diagnostic dose are:
- Nausea
- Vomiting
- Flushing
- Upset stomach
Sources: FDA prescribing information for ChiRhoStim; a study of secretin-stimulated pancreatic imaging (Sherman et al., Gastroenterology, 2014, DOI: 10.1053/j.gastro.2014.05.035), indexed on PubMed; historical accounts of the Bayliss and Starling discovery of secretin. This document is educational and does not constitute medical advice.
Registered human trials
0 registered human trials on ClinicalTrials.gov that we reviewed
Sources
- [1]
- [2]
Compare every peptide’s status in the peptide regulatory status database
More for Hormones & metabolism
View all hormones & metabolism peptides →- FDA-approved Hormones & metabolism
Albiglutide
Albiglutide is a once-weekly GLP-1 receptor agonist made by fusing GLP-1 analog chains to human albumin, approved for type 2 diabetes in 2014 as Tanzeum. It had a somewhat weaker effect on gastric emptying and appetite than some other GLP-1 drugs but showed a cardiovascular benefit in the HARMONY OUTCOMES trial. Despite that, GSK withdrew it from the market in 2018 for commercial reasons, so it remains FDA-approved but is no longer available.
- Not FDA-approved Hormones & metabolism
Compounded-Tesamorelin
Tesamorelin is an FDA-approved growth-hormone-releasing peptide, sold as Egrifta, for excess abdominal fat in HIV-associated lipodystrophy. In a randomized trial of 404 people with HIV (Falutz 2010), visceral fat fell 10.9% on tesamorelin versus 0.6% on placebo over 6 months. Its off-label use for body composition and anti-aging in people without HIV is not an approved indication and lacks dedicated trials. It is banned in sport.
- FDA-approved Hormones & metabolism
Corticotropin
ACTH
Corticotropin (adrenocorticotropic hormone, or ACTH; sold as Acthar Gel and Purified Cortrophin Gel) is a hormone preparation that stimulates the adrenal glands to make their own steroids and also acts directly on immune cells. It is one of the oldest biologic medicines, used today for conditions ranging from infantile spasms to multiple sclerosis relapses. It has been FDA-approved in the U.S. since 1952 and is given as a long-acting injection.
- FDA-approved Hormones & metabolism
Cosyntropin
Cosyntropin (sold as Cortrosyn) is a synthetic fragment of adrenocorticotropic hormone used as a diagnostic agent to test whether the adrenal glands are working. A dose is given and the resulting rise in cortisol shows how well the adrenals respond. It has long been FDA-approved in the U.S. and is given as a single injection during the test.
- FDA-approved Hormones & metabolism
Dulaglutide
Dulaglutide is a once-weekly GLP-1 receptor agonist built by fusing two GLP-1 analog chains to an antibody fragment, which extends its action to about five days. It was approved for type 2 diabetes in 2014 and gained a cardiovascular indication in 2020 after the REWIND trial showed a roughly 12% reduction in major cardiovascular events. It remains on the market as Trulicity.
- In clinical trials Hormones & metabolism
Efpeglenatide
Efpeglenatide is an investigational long-acting GLP-1 receptor agonist, originally developed by Hanmi Pharmaceutical, given as a once-weekly injection for type 2 diabetes and cardiovascular risk. In a large Phase 3 outcomes trial it reduced major cardiovascular events in people with type 2 diabetes. As of 2026, it has not reached approval in major markets.